mRNA-1083
- Generic Name
- mRNA-1083
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults β₯50 Years of Age
Phase 3
Recruiting
- Conditions
- COVID-19Influenza
- Interventions
- Biological: Licensed Influenza VaccineOther: Placebo
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 2450
- Registration Number
- NCT06694389
- Locations
- π―π΅
Fukuoka Heartnet Hospital, Fukuoka-shi, Fukuoka, Japan
π―π΅Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical, Sapporo-shi, Hokkaido, Japan
π―π΅Motomachi Takatsuka Naika Clinic - Internal Medicine, Yokohama-shi, Kanagawa, Japan
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
Phase 2
Active, not recruiting
- Conditions
- SARS-CoV-2Influenza
- Interventions
- Biological: mRNA-1083
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 932
- Registration Number
- NCT06508320
- Locations
- πΊπΈ
Indago Research & Health Center, Inc., Hialeah, Florida, United States
πΊπΈCenexel RCA, Hollywood, Florida, United States
πΊπΈSuncoast Research Group, LLC DBA Flourish Research, Miami, Florida, United States
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
Phase 1
Completed
- Conditions
- InfluenzaSARS-CoV-2
- Interventions
- Biological: Investigational COVID-19 Vaccine 1Biological: COVID-19 Vaccine 1Biological: Influenza Vaccine 2Biological: Investigational Influenza Vaccine 1Biological: Influenza Vaccine 1Biological: Investigational Influenza Vaccine 2Biological: COVID-19 Vaccine 2Biological: Investigational COVID-19 Vaccine 2
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1763
- Registration Number
- NCT05827926
- Locations
- πΊπΈ
Centricity Research, Columbus, Ohio, United States
πΊπΈTexas Center for Drug Development, Houston, Texas, United States
πΊπΈTekton Research, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath